Market Intelligence for Cell Cycle Inhibitors, Clinical Progress, and High-Purity Reagents for CCND2-Targeted Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCND2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCND2 Recombinant Protein (Full Length) High purity (>95%), E. coli or HEK293 Expressed. Sequence Verified. Theoretical MW confirmed. |
View CCND2 Products |
| Protein Complex | CCND2-CDK4/6 Complex (Pre-formed) For PPI disruption assays. High purity heterodimer. |
View CCND2 Products |
| Gene Delivery | CCND2 Lentivirus / Promise-ORF Plasmid Full-length ORF for stable cell line construction. |
View CCND2 Products |
| Benchmark Ab | Anti-Cyclin D2 (Research Grade) Rabbit monoclonal, validated for Western/IP. |
View CCND2 Products |
| Validator | CCND2 siRNA Set (3 unique targets) For knockdown verification and specificity control. |
View CCND2 Products |
| Related Target | CCND1 (Cyclin D1) Primary homolog, sequence identity ~60%. Critical for selectivity screening. |
View CCND1 Products |
| Related Target | CCND3 (Cyclin D3) Alternative D-type cyclin. Off-target liability assessment. |
View CCND3 Products |
| Binding Partner | CDK4 Serine/threonine kinase partner for functional assays. |
View CDK4 Products |
| Binding Partner | CDK6 Alternative kinase partner, hematopoietic focus. |
View CDK6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Interface Targeting & PROTAC/Glue Screening | Pre-formed CCND2-CDK4/6 heterodimer complexes available with >95% purity, endotoxin <1EU/µg; supports ternary complex formation assays |
| Cyclin D Family Selectivity (CCND1/2/3) | Ortholog panel proteins strictly verified by mass spec; sequence divergence mapped for epitope selection |
| Cellular Context Validation | Lentivirus particles for stable CCND2-overexpression cell lines; preserve native folding for functional assays |
| Compound Permeability Screening | Cell-based assay ready: HEK293 expressed CCND2 maintains physiological phosphorylation sites |
| False Positive Elimination | CCND2-specific siRNA included for target engagement confirmation |
Molecular Characteristics and Key Mutations
According to UniProt P30279, CCND2 contains a Cyclin N-terminal domain. Key mutations include rs3217921 (dbSNP), rs587777618 (associated with MPPH3), and rs587777620 (associated with MPPH3). These variants are critical for understanding resistance mechanisms and designing selective degraders.
Live CCND2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CCND2 is evolving rapidly as the limitations of pan-CDK4/6 inhibitors become apparent. Resistance often emerges via amplification or upregulation of Cyclin D2 (CCND2). While first-generation CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) indirectly suppress CCND2 function, the field is pivoting toward direct CCND2 degradation via PROTACs and molecular glues. This shift addresses the compensatory upregulation of CCND2 observed in resistance mechanisms to endocrine therapy and chemotherapy. The primary R&D focus is overcoming acquired endocrine and kinase inhibitor resistance in hematological malignancies and solid tumors.
As second-generation modalities enter preclinical development, the next wave of R&D focuses on isoform-selective degradation (distinguishing CCND2 from CCND1/CCND3) and brain-penetrant degraders for central nervous system malignancies where CCND2 amplification drives progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC Degraders | Arvinas, Cullgen, Nurix, Kymera | Breast Cancer, Lymphoma, Multiple Myeloma | Cell-based degradation assays (Need CCND2-Lentivirus stable lines) & ternary complex formation (Need pure CCND2-CDK4/6 complexes) |
| Molecular Glues | Monte Rosa, C4 Therapeutics | Multiple Myeloma | Ternary complex formation (Need pure CCND2-CDK4/6 complexes) |
| CDK4/6 Inhibitors (indirect) | Pfizer, Novartis, Eli Lilly | HR+ Breast Cancer, HR+/HER2- Breast Cancer | Resistance mutation screening (CCND2 amplification detection) |
| Antisense Oligonucleotides / RNAi | Ionis (preclinical), Academic/Emerging Biotech | Hematological Malignancies, Mantle Cell Lymphoma | Target engagement assays (Need CCND2 protein quantification standards) & knockdown validation (Need highly specific siRNA & Lentivirus) |